Stock AnalizKrystal Biotech, Inc. KRYS
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2017 · data as of November 13, 2026
Krystal Biotech, Inc. (KRYS) is a healthcare company listed in the US with a market value of about $9.0B. In the twelve months to September 30, 2026 it had revenue of $470M and net income of $225M, a net margin of 47.9%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (5/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 41.4, a price to free cash flow of 29.2, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% above the current price.
Score: 2.0 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $470M | $389M | $291M | $51M | $0 | $0 | — | — | — | — | — |
| Net income | $225M | $205M | $89M | $11M | -$140M | -$70M | -$32M | -$19M | -$11M | -$8M | -$1M |
| Free cash flow | $310M | $189M | $119M | -$101M | -$154M | -$116M | -$41M | -$25M | -$12M | -$4M | -$1M |
| EPS (diluted) | $7.37 | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 | $-1.71 | $-1.20 | $-0.97 | $-1.48 | $-1.31 |
| Net margin | 47.9% | 52.6% | 30.7% | 21.6% | — | — | — | — | — | — | — |
| ROIC | — | 10.4% | 6.5% | -11.8% | -27.3% | -11.3% | -8.8% | -8.5% | -8.3% | -7.6% | -43.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $388.22, 27% above the current price; targets range from $284.00 to $474.00; the consensus rating is “Strong buy”; expected EPS is $8.01 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Krystal Biotech’s P/E ratio?
About 41.4, based on the last twelve months of diluted earnings per share (forward P/E about 34.2).
Is Krystal Biotech stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 30% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Krystal Biotech pay a dividend?
Not currently.
Is Krystal Biotech a good stock to buy?
We do not give buy or sell advice. Krystal Biotech scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.